GCT has solid experience in Oncology (see some examples in the table below). We know the sites which count hundreds in the region. GCT has established close relations with key opinion leaders in oncology and is ready to recommend you the best combination in terms of recruitment speed and local regulations, geography and logistics, experience and costs (PI and site fees), equipment (CT/MRI, PET, radiology department, etc.) and standards of treatment applied.
| Phase | # Pnts | # Sites | Countries | Indication | Sponsor |
|---|---|---|---|---|---|
| III | 20 | 6 | Ukraine | Non-Hodgkin's lymphoma | Russian biotech |
| III/IV | 35 | 8 | Ukraine | Breast Cancer | US biopharma |
| IV | 50 | 3 | Russia | Advanced prostate cancer | NPO |
| II | 40 | 15 | Russia | Prostate Cancer | EU Pharma |
| IIb | 51 | 13 | Russia | Prostate Cancer | EU Pharma |
| III | 160 | 12 | Russia | Chemotherapy-induced nausea and vomiting | UK pharma |
| III | 80 | 5 | Russia | Metastatic Breast Cancer | NPO |
| II | 67 | 2 | Russia | Breast Cancer | NPO |
| IIb | 370 | 12 | Russia | Prostate Cancer | EU Pharma |
| I/BE | 45 | 10 | Ukraine | Ovarian cancer, fallopian tube and primary peritoneal cancers | US Pharma |
| II/III | 111 | 1 | Russia | Metastatic Breast Cancer | Russian biotech |
| IIa | 75 | 13 | Russia | Advanced Solid Tumors | US Biotech |
Hundreds of Phase I-IV ICH-GCP international cancer- treatment clinical trials are conducted in Russia, Ukraine, Romania and Bulgaria annually. Oncology clinical research projects rank in the first place among all therapeutic areas in the region ranging from 15% to 25% in share. In the region with the total population around 220m and with the centralized healthcare system patients’ recruitment potential, including treatment-naive subjects, is enormous, which is especially attractive for late-stage international clinical research projects.
The quality of clinical research data coming from Russia and CEE region is comparatively high. For example, the percentage of FDA/EMA approved drugs studied within international clinical trials placed in part in Russia is increasing (29% in 2010, 33% in 2011, 37% in 2012, and 65% in 2013). As per the EMA report of 08-Apr-2013, Russia is among five top-enrolling countries in clinical research worldwide. Moreover, including Russia into your clinical study, you escape the need to conduct local registration clinical studies in future and save time and costs to launch to the Russian market!
More information
We will be happy to provide more information about Oncology studies in CEE and Russia. Please contact us or simply use the form below. A representative will respond shortly.
